儿童ALK阳性无性大细胞淋巴瘤复发的结果:法国儿科肿瘤学会(SFCE)队列中75名法国儿童的真实经历。

IF 2.4 3区 医学 Q2 HEMATOLOGY
Victor Pereira, Maël Barthoulot, Nathalie Aladjidi, Audrey Contet, Jean-Hugues Dalle, Marie Émilie Dourthe, Nathalie Garnier, Bénédicte Bruno, Amaury Leruste, Isabelle Pellier, Matthieu Simonin, Catherine Paillard, Arnauld Verschuur, Stéphane Ducassou, Laurence Lamant, Laurence Brugieres, Marie-Cécile Le Deley, Charlotte Rigaud
{"title":"儿童ALK阳性无性大细胞淋巴瘤复发的结果:法国儿科肿瘤学会(SFCE)队列中75名法国儿童的真实经历。","authors":"Victor Pereira,&nbsp;Maël Barthoulot,&nbsp;Nathalie Aladjidi,&nbsp;Audrey Contet,&nbsp;Jean-Hugues Dalle,&nbsp;Marie Émilie Dourthe,&nbsp;Nathalie Garnier,&nbsp;Bénédicte Bruno,&nbsp;Amaury Leruste,&nbsp;Isabelle Pellier,&nbsp;Matthieu Simonin,&nbsp;Catherine Paillard,&nbsp;Arnauld Verschuur,&nbsp;Stéphane Ducassou,&nbsp;Laurence Lamant,&nbsp;Laurence Brugieres,&nbsp;Marie-Cécile Le Deley,&nbsp;Charlotte Rigaud","doi":"10.1002/pbc.31397","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To describe treatments and outcomes of French children treated for relapsed/refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted the analysis of a series of 75 French children treated for a first relapsed/refractory ALK+ ALCL between 1999 and 2017.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median time to first relapse was 8.1 months from initial diagnosis (2.9 after end of treatment), with 12 relapses during frontline treatment or within 1 month of the end of treatment. Treatment of the first relapse varied according to the period of time and risk factors: 48 received multiagent chemotherapy, including 21 and 19 consolidated with allogeneic stem cell transplantation (SCT) and autologous-SCT, respectively. Twenty-one patients received weekly vinblastine, and six received ALK inhibitors (ALKi). Overall, 64/75 patients reached a second complete remission (CR2). Eight out of 11 patients who did not reach CR2 died and the other three were rescued with ALKi, vinblastine, and nivolumab. With a median follow-up of 8.2 years, 60 patients are alive, 43 in CR2, 15 in CR3, two in CR4; and 15 patients died, six from toxicity and nine from disease progression. The 5-year event-free survival and overall survival after first relapse were 51.7% (95% confidence interval [CI]: 39.6%–62.6%) and 80.7% (95% CI: 69.6%–88.1%), respectively. Time to relapse greater than 12 months from initial diagnosis was proven to be a prognostic factor in relapsed/refractory ALK+ ALCL.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In relapsed ALK+ ALCL, high survival rate can be reached with various therapeutic strategies. The main challenge remains to prevent subsequent relapses, and to lower long-term morbidity.</p>\n </section>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31397","citationCount":"0","resultStr":"{\"title\":\"Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children\",\"authors\":\"Victor Pereira,&nbsp;Maël Barthoulot,&nbsp;Nathalie Aladjidi,&nbsp;Audrey Contet,&nbsp;Jean-Hugues Dalle,&nbsp;Marie Émilie Dourthe,&nbsp;Nathalie Garnier,&nbsp;Bénédicte Bruno,&nbsp;Amaury Leruste,&nbsp;Isabelle Pellier,&nbsp;Matthieu Simonin,&nbsp;Catherine Paillard,&nbsp;Arnauld Verschuur,&nbsp;Stéphane Ducassou,&nbsp;Laurence Lamant,&nbsp;Laurence Brugieres,&nbsp;Marie-Cécile Le Deley,&nbsp;Charlotte Rigaud\",\"doi\":\"10.1002/pbc.31397\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To describe treatments and outcomes of French children treated for relapsed/refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted the analysis of a series of 75 French children treated for a first relapsed/refractory ALK+ ALCL between 1999 and 2017.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The median time to first relapse was 8.1 months from initial diagnosis (2.9 after end of treatment), with 12 relapses during frontline treatment or within 1 month of the end of treatment. Treatment of the first relapse varied according to the period of time and risk factors: 48 received multiagent chemotherapy, including 21 and 19 consolidated with allogeneic stem cell transplantation (SCT) and autologous-SCT, respectively. Twenty-one patients received weekly vinblastine, and six received ALK inhibitors (ALKi). Overall, 64/75 patients reached a second complete remission (CR2). Eight out of 11 patients who did not reach CR2 died and the other three were rescued with ALKi, vinblastine, and nivolumab. With a median follow-up of 8.2 years, 60 patients are alive, 43 in CR2, 15 in CR3, two in CR4; and 15 patients died, six from toxicity and nine from disease progression. The 5-year event-free survival and overall survival after first relapse were 51.7% (95% confidence interval [CI]: 39.6%–62.6%) and 80.7% (95% CI: 69.6%–88.1%), respectively. Time to relapse greater than 12 months from initial diagnosis was proven to be a prognostic factor in relapsed/refractory ALK+ ALCL.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>In relapsed ALK+ ALCL, high survival rate can be reached with various therapeutic strategies. The main challenge remains to prevent subsequent relapses, and to lower long-term morbidity.</p>\\n </section>\\n </div>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\"72 1\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31397\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31397\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31397","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的描述治疗复发/难治性无细胞大细胞淋巴瘤(ALK+ ALCL)的法国儿童的治疗方法和结果:我们对1999年至2017年间接受首次复发/难治性ALK+ ALCL治疗的75名法国儿童进行了系列分析:首次复发的中位时间为初诊后8.1个月(治疗结束后2.9个月),其中12例在一线治疗期间或治疗结束后1个月内复发。首次复发的治疗因时间和风险因素而异:48人接受了多药化疗,其中21人和19人分别接受了异基因干细胞移植(SCT)和自体干细胞移植。21名患者每周接受一次长春新碱治疗,6名患者接受ALK抑制剂(ALKi)治疗。总的来说,64/75名患者达到了第二次完全缓解(CR2)。在未达到CR2的11名患者中,有8名患者死亡,另外3名患者经ALKi、长春新碱和尼伐单抗治疗后获救。中位随访时间为8.2年,60名患者存活,其中43人达到CR2,15人达到CR3,2人达到CR4;15名患者死亡,其中6人死于毒性,9人死于疾病进展。首次复发后的5年无事件生存率和总生存率分别为51.7%(95%置信区间[CI]:39.6%-62.6%)和80.7%(95%置信区间[CI]:69.6%-88.1%)。复发时间超过初始诊断后12个月被证明是复发/难治性ALK+ ALCL的预后因素:结论:对于复发的ALK+ ALCL,各种治疗策略都能达到较高的生存率。结论:对于复发的 ALK+ ALCLL,各种治疗策略都能达到较高的存活率,主要的挑战仍然是如何预防后续复发和降低长期发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children

Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children

Objective

To describe treatments and outcomes of French children treated for relapsed/refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL).

Methods

We conducted the analysis of a series of 75 French children treated for a first relapsed/refractory ALK+ ALCL between 1999 and 2017.

Results

The median time to first relapse was 8.1 months from initial diagnosis (2.9 after end of treatment), with 12 relapses during frontline treatment or within 1 month of the end of treatment. Treatment of the first relapse varied according to the period of time and risk factors: 48 received multiagent chemotherapy, including 21 and 19 consolidated with allogeneic stem cell transplantation (SCT) and autologous-SCT, respectively. Twenty-one patients received weekly vinblastine, and six received ALK inhibitors (ALKi). Overall, 64/75 patients reached a second complete remission (CR2). Eight out of 11 patients who did not reach CR2 died and the other three were rescued with ALKi, vinblastine, and nivolumab. With a median follow-up of 8.2 years, 60 patients are alive, 43 in CR2, 15 in CR3, two in CR4; and 15 patients died, six from toxicity and nine from disease progression. The 5-year event-free survival and overall survival after first relapse were 51.7% (95% confidence interval [CI]: 39.6%–62.6%) and 80.7% (95% CI: 69.6%–88.1%), respectively. Time to relapse greater than 12 months from initial diagnosis was proven to be a prognostic factor in relapsed/refractory ALK+ ALCL.

Conclusion

In relapsed ALK+ ALCL, high survival rate can be reached with various therapeutic strategies. The main challenge remains to prevent subsequent relapses, and to lower long-term morbidity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信